Comparative genomics analysis of mycobacterium ulcerans for the identification of putative essential genes and therapeutic candidates

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Butt, Azeem Mehmood ^a   Nasrullah, Izza ^b   Tahir, Shifa ^b   Tong, Yigang ^c  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

^b QUAID I AZAM UNIVERSITY   (Pakistan)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMINOACYL TRANSFER RNA; BACTERIAL PROTEIN; CARBOHYDRATE; FOLIC ACID; HISTIDINE; PEPTIDOGLYCAN; POLYKETIDE; THIAMINE;

AMINO ACID METABOLISM; ARTICLE; BACTERIAL CELL WALL; BACTERIAL GENE; BACTERIAL GENOME; BACTERIAL METABOLISM; BACTERIAL SECRETION SYSTEM; BACTERIAL VIRULENCE; CARBOHYDRATE METABOLISM; CODON; CONTROLLED STUDY; ESSENTIAL GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE SEQUENCE; GENE TARGETING; GENETIC ASSOCIATION; GENOME ANALYSIS; MOLECULAR DYNAMICS; MYCOBACTERIUM ULCERANS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; SEQUENCE HOMOLOGY; VITAMIN METABOLISM;

DRUG DISCOVERY; ENZYMES; GENES, ESSENTIAL; GENOME, BACTERIAL; GENOMICS; METABOLIC NETWORKS AND PATHWAYS; MYCOBACTERIUM ULCERANS;

EID: 84865058687     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043080     Document Type: Article

References (87)

1. Portaels F, Silva MT, Meyers WM, ((2009)) Buruli ulcer. Clin Dermatol 27:: 291--305.
2. Johnson PD, Stinear T, Small PL, Pluschke G, Merritt RW, et al. ((2005)) Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med 2:: e108.
3. Stinear TP, Jenkin GA, Johnson PD, Davies JK, ((2000)) Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J Bacteriol 182:: 6322--6330.
4. Stinear TP, Seemann T, Pidot S, Frigui W, Reysset G, et al. ((2007)) Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer. Genome Res 17:: 192--200.
5. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, et al. ((2004)) Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A 101:: 1345--1349.
6. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, et al. ((2005)) Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49:: 3182--3186.
7. Marsollier L, Honore N, Legras P, Manceau AL, Kouakou H, et al. ((2003)) Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob Agents Chemother 47:: 1228--1232.
8. Zhang T, Bishai WR, Grosset JH, Nuermberger EL, ((2010)) Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. Antimicrob Agents Chemother 54:: 2806--2813.
9. Abadio AK, Kioshima ES, Teixeira MM, Martins NF, Maigret B, et al. ((2011)) Comparative genomics allowed the identification of drug targets against human fungal pathogens. BMC Genomics 12:: 75.
10. Sakharkar KR, Sakharkar MK, Chow VT, ((2004)) A novel genomics approach for the identification of drug targets in pathogens, with special reference to Pseudomonas aeruginosa. In Silico Biol 4:: 355--360.
11. Perumal D, Lim CS, Sakharkar KR, Sakharkar MK, ((2007)) Differential genome analyses of metabolic enzymes in Pseudomonas aeruginosa for drug target identification. In Silico Biol 7:: 453--465.
12. Butt AM, Batool M, Tong Y, ((2011)) Homology modeling, comparative genomics and functional annotation of Mycoplasma genitalium hypothetical protein MG_237. Bioinformation 7:: 299--303.
13. Butt AM, Tahir S, Nasrullah I, Idrees M, Lu J, et al. ((2012)) Mycoplasma genitalium: A comparative genomics study of metabolic pathways for the identification of drug and vaccine targets. Infect Genet Evol 12:: 53--62.
14. Galperin MY, Koonin EV, ((1999)) Searching for drug targets in microbial genomes. Curr Opin Biotechnol 10:: 571--578.
15. Rocha EP, Danchin A, ((2003)) Essentiality, not expressiveness, drives gene-strand bias in bacteria. Nat Genet 34:: 377--378.
16. Gustafson AM, Snitkin ES, Parker SC, DeLisi C, Kasif S, ((2006)) Towards the identification of essential genes using targeted genome sequencing and comparative analysis. BMC Genomics 7:: 265.
17. Saha S, Heber S, ((2006)) In silico prediction of yeast deletion phenotypes. Genet Mol Res 5:: 224--232.
18. Deng J, Deng L, Su S, Zhang M, Lin X, et al. ((2011)) Investigating the predictability of essential genes across distantly related organisms using an integrative approach. Nucleic Acids Res 39:: 795--807.
19. Shanmugam A, Natarajan J, ((2010)) Computational genome analyses of metabolic enzymes in Mycobacterium leprae for drug target identification. Bioinformation 4:: 392--395.
20. Chong CE, Lim BS, Nathan S, Mohamed R, ((2006)) In silico analysis of Burkholderia pseudomallei genome sequence for potential drug targets. In Silico Biol 6:: 341--346.
21. Morya VK, Dewaker V, Mecarty SD, Singh R, ((2010)) In silico Analysis of Metabolic Pathways for Identification of Putative Drug Targets for Staphylococcus aureus. J Comput Sci Syst Biol 3:: 062--069.
22. Amineni U, Pradhan D, Marisetty H, ((2010)) In silico identification of common putative drug targets in Leptospira interrogans. J Chem Biol 3:: 165--173.
23. Holman AG, Davis PJ, Foster JM, Carlow CK, Kumar S, ((2009)) Computational prediction of essential genes in an unculturable endosymbiotic bacterium, Wolbachia of Brugia malayi. BMC Microbiol 9:: 243.
24. Zhang R, Lin Y, ((2009)) DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes. Nucleic Acids Res 37:: D455--458.
25. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, et al. ((2006)) From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34:: D354--357.
26. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M, ((2010)) KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 38:: D355--360.
27. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. ((1997)) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:: 3389--3402.
28. Aguero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, et al. ((2008)) Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov 7:: 900--907.
29. Boeckmann B, Bairoch A, Apweiler R, Blatter MC, Estreicher A, et al. ((2003)) The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res 31:: 365--370.
30. Lin H, Ding H, Guo FB, Huang J, ((2010)) Prediction of subcellular location of mycobacterial protein using feature selection techniques. Mol Divers 14:: 667--671.
31. Krogh A, Larsson B, von Heijne G, Sonnhammer EL, ((2001)) Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 305:: 567--580.
32. Bernsel A, Viklund H, Hennerdal A, Elofsson A, ((2009)) TOPCONS: consensus prediction of membrane protein topology. Nucleic Acids Res 37:: W465--468.
33. Bernstein FC, Koetzle TF, Williams GJ, Meyer EF Jr, Brice MD, et al. ((1977)) The Protein Data Bank. A computer-based archival file for macromolecular structures. Eur J Biochem 80:: 319--324.
34. Pieper U, Webb BM, Barkan DT, Schneidman-Duhovny D, Schlessinger A, et al. ((2011)) ModBase, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res 39:: D465--474.
35. Cheng AC, Coleman RG, Smyth KT, Cao Q, Soulard P, et al. ((2007)) Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 25:: 71--75.
36. Keller TH, Pichota A, Yin Z, ((2006)) A practical view of 'druggability'. Curr Opin Chem Biol 10:: 357--361.
37. Knox C, Law V, Jewison T, Liu P, Ly S, et al. ((2011)) DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 39:: D1035--1041.
38. Duffield M, Cooper I, McAlister E, Bayliss M, Ford D, et al. ((2010)) Predicting conserved essential genes in bacteria: in silico identification of putative drug targets. Mol Biosyst 6:: 2482--2489.
39. Lin Y, Gao F, Zhang CT, ((2010)) Functionality of essential genes drives gene strand-bias in bacterial genomes. Biochem Biophys Res Commun 396:: 472--476.
40. Lin Y, Zhang RR, ((2011)) Putative essential and core-essential genes in Mycoplasma genomes. Sci Rep 1:: 53.
41. Gao F, Zhang CT, ((2008)) Ori-Finder: a web-based system for finding oriCs in unannotated bacterial genomes. BMC Bioinformatics 9:: 79.
42. Vetrivel U, Arunkumar V, Dorairaj S, ((2007)) ACUA: a software tool for automated codon usage analysis. Bioinformation 2:: 62--63.
43. Sharp PM, Li WH, ((1987)) The codon Adaptation Index-a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res 15:: 1281--1295.
44. Seringhaus M, Paccanaro A, Borneman A, Snyder M, Gerstein M, ((2006)) Predicting essential genes in fungal genomes. Genome Res 16:: 1126--1135.
45. Gao F, Zhang RR, ((2011)) Enzymes are enriched in bacterial essential genes. PLoS One 6:: e21683.
46. Barh D, Kumar A, ((2009)) In silico identification of candidate drug and vaccine targets from various pathways in Neisseria gonorrhoeae. In Silico Biol 9:: 225--231.
47. Gerdes S, Edwards R, Kubal M, Fonstein M, Stevens R, et al. ((2006)) Essential genes on metabolic maps. Curr Opin Biotechnol 17:: 448--456.
48. Chhabra G, Sharma P, Anant A, Deshmukh S, Kaushik H, et al. ((2010)) Identification and modeling of a drug target for Clostridium perfringens SM101. Bioinformation 4:: 278--289.
49. Caffrey CR, Rohwer A, Oellien F, Marhofer RJ, Braschi S, et al. ((2009)) A comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni. PLoS One 4:: e4413.
50. Crowther GJ, Shanmugam D, Carmona SJ, Doyle MA, Hertz-Fowler C, et al. ((2010)) Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl Trop Dis 4:: e804.
51. Wang J, Sung WK, Krishnan A, Li KB, ((2005)) Protein subcellular localization prediction for Gram-negative bacteria using amino acid subalphabets and a combination of multiple support vector machines. BMC Bioinformatics 6:: 174.
52. Gardy JL, Brinkman FS, ((2006)) Methods for predicting bacterial protein subcellular localization. Nat Rev Microbiol 4:: 741--751.
53. Thompson DB, Crandall K, Harding SV, Smither SJ, Kitto GB, et al. ((2008)) In silico analysis of potential diagnostic targets from Burkholderia pseudomallei. Trans R Soc Trop Med Hyg 102 Suppl 1: S61--65.
54. Finlay BB, Falkow S, ((1997)) Common themes in microbial pathogenicity revisited. Microbiol Mol Biol Rev 61:: 136--169.
55. Tseng TT, Tyler BM, Setubal JC, ((2009)) Protein secretion systems in bacterial-host associations, and their description in the Gene Ontology. BMC Microbiol 9 (Suppl 1):: S2.
56. Sandkvist M, ((2001)) Type II secretion and pathogenesis. Infect Immun 69:: 3523--3535.
57. Huber CA, Ruf MT, Pluschke G, Kaser M, ((2008)) Independent loss of immunogenic proteins in Mycobacterium ulcerans suggests immune evasion. Clin Vaccine Immunol 15:: 598--606.
58. Feltcher ME, Sullivan JT, Braunstein M, ((2010)) Protein export systems of Mycobacterium tuberculosis: novel targets for drug development? Future Microbiol 5:: 1581--1597.
59. Schneider T, Sahl HG, ((2010)) An oldie but a goodie- cell wall biosynthesis as antibiotic target pathway. Int J Med Microbiol 300:: 161--169.
60. Vollmer W, Blanot D, de Pedro MA, ((2008)) Peptidoglycan structure and architecture. FEMS Microbiol Rev 32:: 149--167.
61. Gautam A, Vyas R, Tewari R, ((2011)) Peptidoglycan biosynthesis machinery: a rich source of drug targets. Crit Rev Biotechnol 31:: 295--336.
62. Kahan FM, Kahan JS, Cassidy PJ, Kropp H, ((1974)) The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 235:: 364--386.
63. Du W, Brown JR, Sylvester DR, Huang J, Chalker AF, et al. ((2000)) Two active forms of UDP-N-acetylglucosamine enolpyruvyl transferase in gram-positive bacteria. J Bacteriol 182:: 4146--4152.
64. Wilson MD, Boakye DA, Mosi L, Asiedu K, ((2011)) In the case of transmission of mycobacterium ulcerans in buruli ulcer disease acanthamoeba species stand accused. Ghana Med J 45:: 31--34.
65. Li W, Xin Y, McNeil MR, Ma Y, ((2006)) rmlB and rmlC genes are essential for growth of mycobacteria. Biochem Biophys Res Commun 342:: 170--178.
66. Ma Y, Stern RJ, Scherman MS, Vissa VD, Yan W, et al. ((2001)) Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob Agents Chemother 45:: 1407--1416.
67. Melo A, Glaser L, ((1968)) The mechanism of 6-deoxyhexose synthesis. II. Conversion of deoxythymidine diphosphate 4-keto-6-deoxy-D-glucose to deoxythymidine diphosphate L-rhamnose. J Biol Chem 243:: 1475--1478.
68. Begley TP, Downs DM, Ealick SE, McLafferty FW, Van Loon AP, et al. ((1999)) Thiamin biosynthesis in prokaryotes. Arch Microbiol 171:: 293--300.
69. Du Q, Wang H, Xie J, ((2011)) Thiamin (vitamin B1) biosynthesis and regulation: a rich source of antimicrobial drug targets? Int J Biol Sci 7:: 41--52.
70. Muller IB, Hyde JE, Wrenger C, ((2010)) Vitamin B metabolism in Plasmodium falciparum as a source of drug targets. Trends Parasitol 26:: 35--43.
71. Sassetti CM, Boyd DH, Rubin EJ, ((2003)) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48:: 77--84.
72. Hurdle JG, O'Neill AJ, Chopra I, ((2005)) Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents. Antimicrob Agents Chemother 49:: 4821--4833.
73. Ibba M, Soll D, ((2000)) Aminoacyl-tRNA synthesis. Annu Rev Biochem 69:: 617--650.
74. Raczniak G, Ibba M, Soll D, ((2001)) Genomics-based identification of targets in pathogenic bacteria for potential therapeutic and diagnostic use. Toxicology 160:: 181--189.
75. Macarron R, Mensah L, Cid C, Carranza C, Benson N, et al. ((2000)) A homogeneous method to measure aminoacyl-tRNA synthetase aminoacylation activity using scintillation proximity assay technology. Anal Biochem 284:: 183--190.
76. Gallant P, Finn J, Keith D, Wendler P, ((2000)) The identification of quality antibacterial drug discovery targets: a case study with aminoacyl-tRNA synthetases. Expert Opinion on Therapeutic Targets 4:: 1--9.
77. Pohlmann J, Brotz-Oesterhelt H, ((2004)) New aminoacyl-tRNA synthetase inhibitors as antibacterial agents. Curr Drug Targets Infect Disord 4:: 261--272.
78. Fuller AT, Mellows G, Woolford M, Banks GT, Barrow KD, et al. ((1971)) Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens. Nature 234:: 416--417.
79. Beyer D, Kroll HP, Endermann R, Schiffer G, Siegel S, et al. ((2004)) New class of bacterial phenylalanyl-tRNA synthetase inhibitors with high potency and broad-spectrum activity. Antimicrob Agents Chemother 48:: 525--532.
80. Tao J, Wendler P, Connelly G, Lim A, Zhang J, et al. ((2000)) Drug target validation: lethal infection blocked by inducible peptide. Proc Natl Acad Sci U S A 97:: 783--786.
81. Smith HO, Blessing JA, Vaccarello L, ((2002)) Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 84:: 140--144.
82. Aspinall TV, Joynson DH, Guy E, Hyde JE, Sims PF, ((2002)) The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis. J Infect Dis 185:: 1637--1643.
83. Nzila A, ((2006)) Inhibitors of de novo folate enzymes in Plasmodium falciparum. Drug Discov Today 11:: 939--944.
84. Zuccotto F, Martin AC, Laskowski RA, Thornton JM, Gilbert IH, ((1998)) Dihydrofolate reductase: a potential drug target in trypanosomes and leishmania. J Comput Aided Mol Des 12:: 241--257.
85. Hasan S, Daugelat S, Rao PS, Schreiber M, ((2006)) Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. PLoS Comput Biol 2:: e61.
86. Cho Y, Ioerger TR, Sacchettini JC, ((2008)) Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening. J Med Chem 51:: 5984--5992.
87. Henriksen ST, Liu J, Estiu G, Oltvai ZN, Wiest O, ((2010)) Identification of novel bacterial histidine biosynthesis inhibitors using docking, ensemble rescoring, and whole-cell assays. Bioorg Med Chem 18:: 5148--5156.